166 related articles for article (PubMed ID: 35084544)
1. Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome.
Kretschmer A; Tutrone R; Alter J; Berg E; Fischer C; Kumar S; Torkler P; Tadigotla V; Donovan M; Sant G; Skog J; Noerholm M
World J Urol; 2022 Apr; 40(4):983-989. PubMed ID: 35084544
[TBL] [Abstract][Full Text] [Related]
2. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies.
Margolis E; Brown G; Partin A; Carter B; McKiernan J; Tutrone R; Torkler P; Fischer C; Tadigotla V; Noerholm M; Donovan MJ; Skog J
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):296-301. PubMed ID: 34593984
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
4. Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy.
Kretschmer A; Kajau H; Margolis E; Tutrone R; Grimm T; Trottmann M; Stief C; Stoll G; Fischer CA; Flinspach C; Albrecht A; Meyer L; Priewasser T; Enderle D; Müller R; Torkler P; Alter J; Skog J; Noerholm M
Sci Rep; 2022 Mar; 12(1):4777. PubMed ID: 35314720
[TBL] [Abstract][Full Text] [Related]
5. Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen.
Eyrich NW; Wei JT; Niknafs YS; Siddiqui J; Ellimoottil C; Salami SS; Palapattu GS; Mehra R; Kunju LP; Tomlins SA; Chinnaiyan AM; Morgan TM; Tosoian JJ
Urol Oncol; 2022 Jan; 40(1):4.e1-4.e7. PubMed ID: 34753659
[TBL] [Abstract][Full Text] [Related]
6. Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance.
Audenet F; Rozet F; Resche-Rigon M; Bernard R; Ingels A; Prapotnich D; Sanchez-Salas R; Galiano M; Barret E; Cathelineau X
Clin Genitourin Cancer; 2017 Dec; 15(6):e907-e913. PubMed ID: 28522288
[TBL] [Abstract][Full Text] [Related]
7. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
McKiernan J; Noerholm M; Tadigotla V; Kumar S; Torkler P; Sant G; Alter J; Donovan MJ; Skog J
BMC Urol; 2020 Sep; 20(1):138. PubMed ID: 32873277
[TBL] [Abstract][Full Text] [Related]
8. Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis.
Leong JY; Herrera-Caceres JO; Goldberg H; Tham E; Teplitsky S; Gomella LG; Trabulsi EJ; Lallas CD; Fleshner NE; Tilki D; Chandrasekar T
Urology; 2020 Mar; 137():102-107. PubMed ID: 31705947
[TBL] [Abstract][Full Text] [Related]
9. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
[TBL] [Abstract][Full Text] [Related]
10. ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis.
Tutrone R; Lowentritt B; Neuman B; Donovan MJ; Hallmark E; Cole TJ; Yao Y; Biesecker C; Kumar S; Verma V; Sant GR; Alter J; Skog J
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):596-601. PubMed ID: 37193776
[TBL] [Abstract][Full Text] [Related]
11. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Significance of Perineural Invasion by Prostate Cancer on Needle Core Biopsy: Involvement of Single Versus Multiple Sextant Sites.
Bell PD; Teramoto Y; Gurung PMS; Numbere N; Yang Z; Miyamoto H
Arch Pathol Lab Med; 2022 Oct; 146(10):1252-1257. PubMed ID: 35020791
[TBL] [Abstract][Full Text] [Related]
13. Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.
Herlemann A; Buchner A; Kretschmer A; Apfelbeck M; Stief CG; Gratzke C; Tritschler S
World J Urol; 2017 Oct; 35(10):1517-1524. PubMed ID: 28493044
[TBL] [Abstract][Full Text] [Related]
14. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
Kaye DR; Qi J; Morgan TM; Linsell S; Ginsburg KB; Lane BR; Montie JE; Cher ML; Miller DC;
BJU Int; 2019 May; 123(5):846-853. PubMed ID: 30248225
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance.
Perera M; Jibara G; Tin AL; Haywood S; Sjoberg DD; Benfante NE; Carlsson SV; Eastham JA; Laudone V; Touijer KA; Fine S; Scardino PT; Vickers AJ; Ehdaie B
Eur Urol Focus; 2023 Jul; 9(4):662-668. PubMed ID: 36566100
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL.
Tutrone R; Donovan MJ; Torkler P; Tadigotla V; McLain T; Noerholm M; Skog J; McKiernan J
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):607-614. PubMed ID: 32382078
[TBL] [Abstract][Full Text] [Related]
17. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
[TBL] [Abstract][Full Text] [Related]
18. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
Pierorazio PM; Ross AE; Lin BM; Epstein JI; Han M; Walsh PC; Partin AW; Pavlovich CP; Schaeffer EM
BJU Int; 2012 Oct; 110(8):1122-8. PubMed ID: 22373045
[TBL] [Abstract][Full Text] [Related]
19. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
